Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- How I stimulate my mind while caring for my husband with ALS
- Developer gets OK to expand first-in-human trial of ALS therapy to Europe
- Out-of-pocket ALS costs create heavy financial burden for French families
- RAG-17 shows promise in SOD1-ALS trial, reducing damage markers
- Climbing ALS death rates seen in Finland, not due to aging alone: Study